World's Best Scientists 2026 revealed!

D-Index & Metrics

Molecular Biology

D-Index
48
Citations
12970
World Ranking
2662
National Ranking
1299

Overview

Ellen Weisberg is affiliated with Harvard University in the United States. Their research primarily focuses on Medicine, with significant contributions also in Biochemistry, Genetics, and Molecular Biology. Key subfields in which they have published include Molecular Biology, Hematology, Genetics, Oncology, and Infectious Diseases.

The scientist's work spans several main topics, particularly Protein Degradation and Inhibitors, Acute Myeloid Leukemia Research, Ubiquitin and Proteasome Pathways, Multiple Myeloma Research and Treatments, Chronic Lymphocytic Leukemia Research, Histone Deacetylase Inhibitors Research, and Myeloproliferative Neoplasms: Diagnosis and Treatment.

Prominent recent papers authored or co-authored by Ellen Weisberg include:

  • Repurposing of Kinase Inhibitors for Treatment of COVID-19 (2020), published in Pharmaceutical Research
  • BRD9 Degraders as Chemosensitizers in Acute Leukemia and Multiple Myeloma (2022), published in Blood Cancer Journal

Frequent co-authors in their research collaborations include James D. Griffin, Martin Sattler, Chengcheng Meng, Richard M. Stone, and Sara J. Buhrlage.

Ellen Weisberg has contributed to multiple publications in notable venues such as Leukemia, British Journal of Cancer, Journal of Cellular and Molecular Medicine, Cancers, and Blood. These journals are frequently associated with their published work.

Best Publications

  • Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

    Ellen Weisberg;Paul W. Manley;Werner Breitenstein;Josef Brüggen

  • Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

    Ellen Weisberg;Paul W. Manley;Sandra W. Cowan-Jacob;Andreas Hochhaus

  • Smad4 and FAST-1 in the assembly of activin-responsive factor.

    Xin Chen;Ellen Weisberg;Valerie Fridmacher;Minoru Watanabe

  • Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

    Ellen Weisberg;Christina Boulton;Louise M Kelly;Paul Manley

  • AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.

    E Weisberg;P Manley;J Mestan;S Cowan-Jacob

  • Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL–transformed hematopoietic cell lines

    Ellen Weisberg;James D. Griffin

  • Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

    Laurence Catley;Ellen Weisberg;Ellen Weisberg;Tanyel Kiziltepe;Tanyel Kiziltepe;Yu-Tzu Tai;Yu-Tzu Tai

  • A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader

    Hai-Tsang Huang;Dennis Dobrovolsky;Joshiawa Paulk;Guang Yang

  • Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity

    Douglas W McMillin;Jake Delmore;Jake Delmore;Ellen Weisberg;Ellen Weisberg;Joseph M Negri;Joseph M Negri

  • ARG tyrosine kinase activity is inhibited by STI571.

    Keiko Okuda;Keiko Okuda;Ellen Weisberg;Ellen Weisberg;D. Gary Gilliland;D. Gary Gilliland;James D. Griffin;James D. Griffin

  • The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors

    Erik A. Nelson;Erik A. Nelson;Sarah R. Walker;Sarah R. Walker;Ellen Weisberg;Ellen Weisberg;Michal Bar-Natan;Michal Bar-Natan

  • The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.

    Boris Lin;Klaus Podar;Deepak Gupta;Yu-Tzu Tai

  • NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.

    Laurence Catley;Ellen Weisberg;Yu-Tzu Tai;Peter Atadja

  • PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.

    Jan Cools;Elizabeth H Stover;Christina L Boulton;Christina L Boulton;Jason Gotlib

  • Tensin: a potential link between the cytoskeleton and signal transduction.

    Su Hao Lo;Ellen Weisberg;Lan Bo Chen

  • Selective Damage to Carcinoma Mitochondria by the Rhodacyanine MKT-077

    Josephine S. Modica-Napolitano;Keizo Koya;Ellen Weisberg;Brian T. Brunelli

  • Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7

    Ilaria Lamberto;Xiaoxi Liu;Hyuk-Soo Seo;Nathan J. Schauer

  • Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor

    Hyung-Gu Kim;Li Tan;Ellen L. Weisberg;Feiyang Liu

  • Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.

    Benjamin M. F. Mow;Benjamin M. F. Mow;Benjamin M. F. Mow;Joya Chandra;Joya Chandra;Joya Chandra;Phyllis A. Svingen;Phyllis A. Svingen;Phyllis A. Svingen;Christopher G. Hallgren;Christopher G. Hallgren;Christopher G. Hallgren

  • Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib.

    Ellen Weisberg;Abdel Kareem Azab;Paul W. Manley;Andrew L. Kung

Frequent Co-Authors

James D. Griffin
James D. Griffin Harvard University
Nathanael S. Gray
Nathanael S. Gray Stanford University
Martin Sattler
Martin Sattler Harvard University
Richard Stone
Richard Stone Harvard University
Andrew L. Kung
Andrew L. Kung Memorial Sloan Kettering Cancer Center
Constantine S. Mitsiades
Constantine S. Mitsiades Harvard University
Kenneth C. Anderson
Kenneth C. Anderson Harvard University
Nikhil C. Munshi
Nikhil C. Munshi Harvard University
David A. Frank
David A. Frank Harvard University
Dharminder Chauhan
Dharminder Chauhan Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in Molecular Biology, numerous online degree options and accelerated pathways are available in the health and biomedical sciences. Many learners consider streamlined programs such as rn to bsn 6 months to quickly build on a registered nursing credential. These fast-track degrees allow working professionals to advance their qualifications within a shorter time frame.

Another option for those with an Associate of Science in Nursing (ASN) is bridging directly from asn to np programs. These bridges lead nurses into advanced practice roles and greater career flexibility. If you are coming from a non-nursing background but want to enter healthcare, consider msn direct entry programs online that provide a pathway to a master's degree in nursing for career changers.

Deciding which university to choose can also be a challenge. Comparing options like chamberlain vs capella rn to bsn program can help clarify accreditation, curriculum style, credit transfer, and graduate outcomes. With so many flexible online degrees linked to career advancement in biomedical fields, there are options for every background and goal.

Best Scientists Citing Ellen Weisberg

Trending Scientists

Recently Published Articles